scholarly journals A Surveillance-Based Hepatitis C Care Cascade, New York City, 2017

2018 ◽  
Vol 133 (4) ◽  
pp. 497-501 ◽  
Author(s):  
Miranda S. Moore ◽  
Angelica Bocour ◽  
Fabienne Laraque ◽  
Ann Winters
Keyword(s):  
New York ◽  
New York City ◽  
Hepatitis C ◽  
York City ◽  
Population Level ◽  
Health Department ◽  
Department Of Health ◽  
Care Cascade ◽  
Laboratory Surveillance ◽  
Direct Acting

Objectives: The care cascade, a method for tracking population-level progression from diagnosis to cure, is an important tool in addressing and monitoring the hepatitis C virus (HCV) epidemic. However, little agreement exists on appropriate care cascade steps or how best to measure them. The New York City (NYC) Department of Health and Mental Hygiene (DOHMH) sought to construct a care cascade by using laboratory surveillance data with clinically relevant categories that can be readily updated over time. Methods: We identified all NYC residents ever reported to the DOHMH surveillance registry with HCV through June 30, 2017 (n = 175 896). To account for outmigration, death, or treatment before negative RNA results became reportable to the health department, we limited the population to people with any test reported since July 1, 2014. Of these residents, we identified the proportion with a reported positive RNA test and estimated the proportion treated and cured since July 2014 by using DOHMH-developed surveillance-based algorithms. Results: Of 78 886 NYC residents ever receiving a diagnosis of HCV and tested since July 1, 2014, a total of 70 397 (89.2%) had ever been reported as RNA positive through June 30, 2017; 36 875 (46.7%) had initiated treatment since July 1, 2014, and 23 766 (30.1%) appeared cured during the same period. Conclusion: A substantial gap exists between confirming HCV infection and initiating treatment, even in the era of direct-acting antivirals. Using this cascade, we will monitor progress in improved treatment and cure of HCV in NYC.

scholarly journals The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014–2017

2020 ◽  
Vol 27 ◽  
pp. 100567
Author(s):  
Justin Chan ◽  
Fatos Kaba ◽  
Jessie Schwartz ◽  
Angelica Bocour ◽  
Matthew J Akiyama ◽  
...  
Keyword(s):  
New York ◽  
New York City ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
York City ◽  
Antiviral Treatment ◽  
Direct Acting Antiviral ◽  
Care Cascade ◽  
Direct Acting

scholarly journals Hepatitis C Direct Acting Antiviral Therapies in a New York City HIV/AIDS Special Needs Plan: Uptake and Barriers

2015 ◽  
Vol 29 (12) ◽  
pp. 643-645 ◽  
Author(s):  
Mark H. Kuniholm ◽  
Terry Leach ◽  
Joseph Lunievicz ◽  
Noemí Olivo ◽  
Kathryn Anastos ◽  
...  
Keyword(s):  
New York ◽  
New York City ◽  
Hepatitis C ◽  
Special Needs ◽  
York City ◽  
Direct Acting Antiviral ◽  
Antiviral Therapies ◽  
Direct Acting ◽  
Hiv Aids

scholarly journals COVID-19 infection among people with HIV in New York City: A population-level analysis of linked surveillance data

2020 ◽  
Author(s):  
Sarah L Braunstein ◽  
Rachael Lazar ◽  
Amanda Wahnich ◽  
Demetre C Daskalakis ◽  
Oni J Blackstock
Keyword(s):  
New York ◽  
New York City ◽  
York City ◽  
Large Population ◽  
Population Level ◽  
Health Department ◽  
High Poverty ◽  
Hiv Surveillance ◽  
New Yorkers ◽  
Death Data

Abstract Background New York City (NYC) was hard-hit by the SARS-CoV-2 pandemic and is also home to a large population of people with HIV (PWH). Methods We matched lab-confirmed COVID-19 case and death data reported to the NYC Health Department as of June 2, 2020, against the NYC HIV surveillance registry. We describe and compare the characteristics and COVID-19-related outcomes of PWH diagnosed with COVID-19 with all NYC PWH and with all New Yorkers diagnosed with COVID-19. Results Through June 2, 204,583 NYC COVID-19 cases were reported. The registry match identified 2,410 PWH with diagnosed COVID-19 eligible for analysis (1.06% of all COVID-19 cases). Compared with all NYC PWH and all New Yorkers diagnosed with COVID-19, a higher proportion of PWH with COVID-19 were older, male, Black or Latino, and living in high-poverty neighborhoods. At least one underlying condition was reported for 58.9% of PWH with COVID-19. Compared with all NYC COVID-19 cases, a higher proportion of PWH with COVID-19 experienced hospitalization, intensive care unit admission and/or death; most PWH who experienced poor COVID-19-related outcomes had CD4 <500 cells/µL. Conclusions Given NYC HIV prevalence is 1.5%, PWH were not overrepresented among COVID-19 cases. However, compared with NYC COVID-19 cases overall, a greater proportion of PWH had adverse COVID-19-related outcomes, perhaps because of a higher prevalence of factors associated with poor COVID-19 outcomes. Given the pandemic’s exacerbating effects on health inequities, HIV public health and clinical communities must strengthen services and support for people living with and affected by HIV.

scholarly journals Impact of a New York City Health Department Initiative to Expand HIV Partner Services outside Std Clinics

2012 ◽  
Vol 127 (1) ◽  
pp. 107-114 ◽  
Author(s):  
Lorna Thorpe ◽  
Chi-Chi N. Udeagu ◽  
Dipal Shah ◽  
Colin W. Shepard ◽  
Angelica Bocour ◽  
...  
Keyword(s):  
New York ◽  
New York City ◽  
York City ◽  
Health Department

The fate of children vaccinated against tuberculosis according to Salmett's method

1935 ◽  
Vol 31 (1) ◽  
pp. 145-145
Author(s):  
C. Kereszturi ◽  
W. Н. Park ◽  
P. Vogel ◽  
М. Sevine
Keyword(s):  
New York ◽  
New York City ◽  
York City ◽  
Financial Assistance ◽  
Insurance Company ◽  
Careful Observation ◽  
York City Department ◽  
Department Of Health

With financial assistance from the New York City Department of Health and an insurance company, and with the participation of a significant number of technicians, they carried out a study that is noteworthy for the careful observation.

scholarly journals Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City

PLoS ONE ◽  
2018 ◽  
Vol 13 (7) ◽  
pp. e0200269 ◽  
Author(s):  
Hong-Van Tieu ◽  
Oliver Laeyendecker ◽  
Vijay Nandi ◽  
Rebecca Rose ◽  
Reinaldo Fernandez ◽  
...  
Keyword(s):  
New York ◽  
New York City ◽  
Hepatitis C ◽  
York City ◽  
Sex With Men

scholarly journals Post-SARS-CoV-2 monoclonal antibody treatment hospitalizations as a sentinel for emergence of viral variants in New York City

2021 ◽  
Author(s):  
Kelsie Cowman ◽  
Yi Guo ◽  
Liise-anne Pirofski ◽  
David Wong ◽  
Hongkai Bao ◽  
...  
Keyword(s):  
New York ◽  
Monoclonal Antibody ◽  
New York City ◽  
York City ◽  
Human Services ◽  
Antibody Treatment ◽  
Health And Human Services ◽  
Department Of Health ◽  
Monoclonal Antibody Treatment ◽  
The U.S

Abstract We partnered with the U.S. Department of Health and Human Services to treat high-risk, non-admitted COVID-19 patients with bamlanivimab in the Bronx, NY per Emergency Use Authorization criteria. Increasing post-treatment hospitalizations were observed monthly between December 2020-March 2021 in parallel to the emergence of SARS-CoV-2 variants in New York City.

Sign in / Sign up

Export Citation Format

Share Document